IPP Bureau
Philips advances AI-powered diagnostic systems and transformative workflow solutions
By IPP Bureau - November 28, 2022
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
Japan approves ENHERTU for treatment of adult patients with HER2 positive unresectable breast cancer
By IPP Bureau - November 27, 2022
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
Chantal van Gils joins NDA Advisory Board as Director of Epidemiology
By IPP Bureau - November 27, 2022
She will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy
Early detection of lung cancer vital to combat rising mortality rate, says GlobalData
By IPP Bureau - November 27, 2022
The only definitive way to diagnose and stage lung cancers is through biopsies
LPU organizes conference on welfare of global community
By IPP Bureau - November 27, 2022
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
Panchsheel Organics to set up fermentation/API unit
By IPP Bureau - November 27, 2022
Total investment envisaged in this project stands at up to Rs 70 crore
Briefs: IOL Chemicals and Cipla
By IPP Bureau - November 27, 2022
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
Delivery solution provider ZIM Laboratories Limited lists on NSE
By IPP Bureau - November 26, 2022
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
AstraZeneca receives import and market permission from CDSCO for Dapagliflozin
By IPP Bureau - November 26, 2022
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Ministry of Ayush and DST sign MoU to identify areas of research
By IPP Bureau - November 26, 2022
The two have agreed to jointly undertake R&D activities on scientific validation of Ayush concepts, procedures and products
CPHI Frankfurt 2022: Global pharma confidence hits record high in CPHI Pharma Index
By IPP Bureau - November 26, 2022
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
India’s plan for containment of AMR focuses on an integrated One Health approach: Dr. Bharti
By IPP Bureau - November 26, 2022
It serves to leverage the strengths of various institutions to coordinate AMR surveillance lab networks
USFDA inspects Lupin's Mandideep Unit-1 facility
By IPP Bureau - November 25, 2022
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
Laurus Labs takes stake in Ethan Energy India
By IPP Bureau - November 25, 2022
This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant
Neuland Laboratories appoints Abhijit Majumdar as CFO
By IPP Bureau - November 24, 2022
He brings over 30 years of experience across various organizations such as Asian Paints PPG, Berger Paints, Tata Steel, among others
